CSF3 and myelodysplastic syndrome: In addition, a in one study while the absolute risk was low, breast cancer patients treated with G-CSF were significantly more likely (hazard rate ratio = 2.14) to develop myelodysplastic syndrome or acute myeloid leukemia than patients not receiving G-CSF [27].